Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Anakinra treatment in drug-resistant Behcet's disease: a case series.

Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, Simonini G, Borsari G, Caso F, Lucherini OM, Frediani B, Bertoldi I, Punzi L, Galeazzi M, Cimaz R.

Clin Rheumatol. 2015 Jul;34(7):1293-301. doi: 10.1007/s10067-013-2443-8. Epub 2013 Dec 5.

PMID:
24305945
2.

Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.

Grayson PC, Yazici Y, Merideth M, Sen HN, Davis M, Novakovich E, Joyal E, Goldbach-Mansky R, Sibley CH.

Arthritis Res Ther. 2017 Mar 24;19(1):69. doi: 10.1186/s13075-017-1222-3.

3.

Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.

Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Gentileschi S, Bacherini D, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L.

Clin Rheumatol. 2017 Jan;36(1):191-197. doi: 10.1007/s10067-016-3506-4. Epub 2016 Dec 16.

PMID:
27981463
4.

Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection.

Emmi G, Silvestri E, Squatrito D, Vitale A, Bacherini D, Vannozzi L, Emmi L, D'Elios MM, Cantarini L, Prisco D.

Int J Dermatol. 2017 Feb;56(2):218-220. doi: 10.1111/ijd.13337. Epub 2016 Jun 23. No abstract available.

PMID:
27336860
5.

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study.

Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, Olivieri I, Goldoni M, Vitale A, Silvestri E, Prisco D, Lapadula G, Galeazzi M, Iannone F, Cantarini L.

Clin Rheumatol. 2016 May;35(5):1281-6. doi: 10.1007/s10067-015-3004-0. Epub 2015 Jul 10.

PMID:
26156661
6.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
7.
8.

Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series.

Cantarini L, Stromillo ML, Vitale A, Lopalco G, Emmi G, Silvestri E, Federico A, Galeazzi M, Iannone F, De Stefano N.

Isr Med Assoc J. 2016 Mar-Apr;18(3-4):238-42.

9.

Efficacy of anakinra in refractory Behçet's disease sacroiliitis.

Caso F, Rigante D, Vitale A, Lucherini OM, Cantarini L.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S171. Epub 2014 Apr 7. No abstract available.

PMID:
24709061
10.

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome.

Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, Buoncompagni A, Plebani A, Merlini G, Martini A.

Arthritis Rheum. 2008 May;58(5):1516-20. doi: 10.1002/art.23475.

11.

Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy.

Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, Sibilia J, Bourgeois P, Fautrel B; CRI (Club Rhumatismes et Inflammation).

Arthritis Care Res (Hoboken). 2013 May;65(5):822-6. doi: 10.1002/acr.21901.

12.

Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behçet uveitis.

Kuroyanagi K, Sakai T, Kohno H, Okano K, Akiyama G, Aoyagi R, Inaba M, Tsuneoka H.

Jpn J Ophthalmol. 2015 Nov;59(6):401-8. doi: 10.1007/s10384-015-0404-2. Epub 2015 Aug 29.

PMID:
26318435
13.

Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.

Park JY, Chung YR, Lee K, Song JH, Lee ES.

Yonsei Med J. 2015 Jul;56(4):1158-62. doi: 10.3349/ymj.2015.56.4.1158.

14.

Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease.

Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, Anelli MG, Franceschini R, Menicacci C, Galeazzi M, Selmi C, Rigante D.

Autoimmun Rev. 2015 Jan;14(1):1-9. doi: 10.1016/j.autrev.2014.08.008. Epub 2014 Aug 22. Review.

PMID:
25151975
15.

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.

Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P.

Arthritis Rheum. 2010 Jan;62(1):258-67. doi: 10.1002/art.25057.

16.

Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.

Kötter I, Wacker A, Koch S, Henes J, Richter C, Engel A, Günaydin I, Kanz L.

Semin Arthritis Rheum. 2007 Dec;37(3):189-97. Epub 2007 Jun 20. Review.

PMID:
17583775
17.

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.

Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Huong du LT, Lemaitre C, Fradeau C, LeHoang P, Piette JC.

Br J Ophthalmol. 2007 Mar;91(3):335-9. Epub 2006 Oct 18.

18.

Rapid responses to anakinra in patients with refractory adult-onset Still's disease.

Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA.

Arthritis Rheum. 2005 Jun;52(6):1794-803.

19.

Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.

Vitale A, Emmi G, Lopalco G, Gentileschi S, Silvestri E, Fabiani C, Urban ML, Frediani B, Galeazzi M, Iannone F, Rigante D, Cantarini L.

Clin Rheumatol. 2017 Feb;36(2):451-455. doi: 10.1007/s10067-016-3417-4. Epub 2016 Sep 27.

PMID:
27679471
20.

HLA-B51 and its allelic types in association with Behçet's disease and recurrent aphthous stomatitis in Korea.

Chang HK, Kim JU, Cheon KS, Chung HR, Lee KW, Lee IH.

Clin Exp Rheumatol. 2001 Sep-Oct;19(5 Suppl 24):S31-5.

PMID:
11760395

Supplemental Content

Support Center